News for Reviva Pharmaceuticals Holdings, Inc. (RVPH)

Reviva Pharmaceuticals (RVPH) continues to receive a positive outlook as analyst Jason Kolbert from D. Boral Capital maintains a "Buy" rating on the stock.Accor

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 100 points on Thursday. The Dow traded up 0.82% to 43,335.29 while the...

Key Highlights: Reviva Pharmaceuticals Holdings (RVPH) announces pricing for a $10 million public offering. Analysts project a significant upside, with a

Reviva Pharmaceuticals (RVPH) launches a $10 million public offering at $0.50 per share. Offering includes 20 million shares with Series C and D warrant

U.S. stocks traded higher this morning, with the Dow Jones index gaining over 200 points on Thursday. Following the market opening Thursday, the Dow traded up ...

On June 3, 2025, Reviva Pharmaceuticals (RVPH) received a maintained 'Buy' rating from analyst Jason Kolbert at D. Boral Capital. The analyst's rating remains u

Reviva Pharmaceuticals (RVPH) has successfully wrapped up a Phase 3 open-label extension (OLE) study, exploring the long-term effects of brilaroxazine in schizo

Reviva Pharmaceuticals (RVPH) announces positive results from a 1-year Phase 3 study on brilaroxazine for schizophrenia. The study shows a 35% discontin

”“ Robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms ”“ ”“ Generally well-tolerated with l

”“ 446 participants completed the brilaroxazine long-term open-label extension (OLE) trial with 156 completing one-year and 301 completing six months of treatm

Reviva Pharmaceuticals (RVPH) is making significant progress with its late-stage brilaroxazine program, gearing up for key developments in the near future. The

CUPERTINO, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. ( RVPH) (”œReviva” or the ”œCompany”), a late-stage pharmace

CUPERTINO, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. ( RVPH) (”œReviva” or the ”œCompany”), a late-stage pharmace

On December 31, 2024, Schonfeld Strategic Advisors LLC (Trades, Portfolio) made a significant move by reducing its stake in Reviva Pharmaceuticals Holdings Inc

**media[531692]**

Investors with a lot of money to spend have taken a bearish stance on Reviva Pharmaceuticals RVPH. And retail traders should know. We noticed this today when ...

CUPERTINO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. ( RVPH) (”œReviva” or the ”œCompany”), a late-stage pharmaceu

New York-based Syntec Optics Holdings, Inc. (OPTX) is up over 167 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.

Shares of Mitek Systems, Inc. MITK rose sharply in today's pre-market trading after reporting better-than-expected fourth-quarter results. Mitek Systems report...